Skip to main content
. 2020 Jan 21;30(3):614–640. doi: 10.1111/bpa.12812

Figure 1.

Figure 1

BLT1—receptor for the SPM resolvin E1 (RvE1) in different regions of Alzheimer's disease (AD) and control brain. A–C. Sections from the human hippocampus including CA1, CA2, CA3 and the dentate gyrus (DG) from AD and control cases were incubated with antibodies to BLT1. The signal for BLT1 is clearly stronger in AD in all of these areas, with the largest difference in CA2 and CA3. B. The granular appearance of the staining in pyramidal neurons is seen in both control and AD (black and white arrow heads in CA2 and CA3). A similarly strong level of BLT1 immunoreactivity in AD can be seen in neurons in the hilus region, also with a granular appearance. The BLT1 signal is also seen in axons close to the neuronal cell somata (short black arrows in CA3 and hilus). A strong signal for BLT1 is seen in glial cells, also with a granular appearance (black arrow heads in CA2, CA3, hilus and DG (C)). C. Granular cells in the DG are also positive for BLT1 (long black arrows), with markedly stronger staining in AD. Bars = 50 µm. The high magnification micrographs are part of the corresponding low magnification micrographs. BLT1 = leukotriene B4 receptor, CA = cornu Ammonis, SPM = specialized pro‐resolving mediator.